CAS 188039-54-5

palivizumab

Description:

Palivizumab is a monoclonal antibody specifically designed for the prevention of respiratory syncytial virus (RSV) infections in high-risk infants and young children. It is a humanized IgG1 kappa antibody that targets the F protein of RSV, inhibiting the virus's ability to infect cells. Palivizumab is administered via intramuscular injection and is typically given in a series of doses during RSV season. The drug is characterized by its high specificity and affinity for the RSV F protein, which enhances its efficacy in providing passive immunity. Its molecular weight is approximately 148 kDa, and it is produced using recombinant DNA technology in mammalian cell lines. Common side effects may include injection site reactions, fever, and rash, but serious adverse effects are rare. Palivizumab has been shown to significantly reduce the incidence of RSV-related hospitalizations in at-risk populations, making it a critical therapeutic option in pediatric care.

Formula: Unspecified

Synonyms:

• palivizumab

Palivizumab

CAS: 188039-54-5

Palivizumab (MEDI 493) is a humanized RSV-specific monoclonal antibody that selectively inhibits epitopes at the F protein A antigenic site of RSV subtypes A

Purity: SDS-PAGE:93.4%;SEC-HPLC:97.6%

Color and Shape: Liquid

Molecular weight: 144.99 kDa

Ref: TM-T76907

Palivizumab

CAS: 188039-54-5

Palivizumab

Purity: ≥90%

Ref: 54-BUP20262

Palivizumab

CAS: 188039-54-5

Monoclonal antibody against the F protein of RSV

Purity: Min. 95%

Ref: 3D-FP139135